This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Jong, A. Articles by van der Burg, S. H. Search for Related Content PubMed PubMed Citation Articles by de Jong, A. Articles by van der Burg, S. H.

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

Departments of ¹ Immunohematology and Blood Transfusion, ² Clinical Pharmacy and Toxicology, ³ Gynecology, and ⁴ Pathology, Leiden University Medical Center, Leiden, the Netherlands

Cervical cancer is the possible outcome of genital infection with high-risk human papillomavirus (HPV) and is preceded by a phase of persistent HPV infection during which the host immune system fails to eliminate the virus. Fortunately, the majority of genital HPV infections are cleared before the development of (pre)malignant lesions. Analysis of CD4+ T-helper (Th) immunity against the E2, E6, and E7 antigens of HPV16 in healthy women revealed strong proliferative E2- and E6-specific responses associated with prominent IFN- and interleukin 5 secretion. This indicates that the naturally arising virus-induced immune response displays a mixed Th1/Th2 cytokine profile. Of all HPV16+ cervical cancer patients, approximately half failed to mount a detectable immune response against the HPV16-derived peptides. The other half of the patients showed impaired HPV16-specific proliferative responses, which generally lacked both IFN- and interleukin 5. This indicates that the HPV16-specific CD4+ T-cell response in cervical cancer patients is either absent or severely impaired, despite a relatively good immune status of the patients, as indicated by intact responses against recall antigens. It is highly conceivable that proper CD4+ T-cell help is important for launching an effective immune attack against HPV because infection of cervical epithelia by this virus is, at least initially, not accompanied by gross disturbance of this tissue and/or strong proinflammatory stimuli. Therefore, our observations concerning the lack of functional HPV16-specific CD4+ T-cell immunity in patients with cervical cancer offer a possible explanation for the development of this disease.

This article has been cited by other articles:

				G. G. Kenter, M. J.P. Welters, A. R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P.G. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al. Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia N. Engl. J. Med., November 5, 2009; 361(19): 1838 - 1847. [Abstract] [Full Text] [PDF]

				R. Karim, E. S. Jordanova, S. J. Piersma, G. G. Kenter, L. Chen, J. M. Boer, C. J. M. Melief, and S. H. van der Burg Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma Clin. Cancer Res., October 15, 2009; 15(20): 6341 - 6347. [Abstract] [Full Text] [PDF]

				A. P. Lepique, K. R. P. Daghastanli, I. M. Cuccovia, and L. L. Villa HPV16 Tumor Associated Macrophages Suppress Antitumor T Cell Responses Clin. Cancer Res., July 1, 2009; 15(13): 4391 - 4400. [Abstract] [Full Text] [PDF]

				F. M. Speetjens, P. J.K. Kuppen, M. J.P. Welters, F. Essahsah, A. M. E.G. Voet van den Brink, M. G. K. Lantrua, A. R. P.M. Valentijn, J. Oostendorp, L. M. Fathers, H. W. Nijman, et al. Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer Clin. Cancer Res., February 1, 2009; 15(3): 1086 - 1095. [Abstract] [Full Text] [PDF]

				C. L. Trimble, S. Peng, F. Kos, P. Gravitt, R. Viscidi, E. Sugar, D. Pardoll, and T.C. Wu A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3 Clin. Cancer Res., January 1, 2009; 15(1): 361 - 367. [Abstract] [Full Text] [PDF]

				P. J. de Vos van Steenwijk, S. J. Piersma, M. J.P. Welters, J. M. van der Hulst, G. Fleuren, B. W.J. Hellebrekers, G. G. Kenter, and S. H. van der Burg Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response Clin. Cancer Res., November 15, 2008; 14(22): 7188 - 7195. [Abstract] [Full Text] [PDF]

				O. C. Goodyear, G. Pratt, A. McLarnon, M. Cook, K. Piper, and P. Moss Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma Blood, October 15, 2008; 112(8): 3362 - 3372. [Abstract] [Full Text] [PDF]

				S. Vaccarella, R. Herrero, P. J F Snijders, M. Dai, J. O Thomas, N. T. Hieu, C. Ferreccio, E. Matos, H. Posso, S. de Sanjose, et al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys Int. J. Epidemiol., June 1, 2008; 37(3): 536 - 546. [Abstract] [Full Text] [PDF]

				H. Echchannaoui, M. Bianchi, D. Baud, M. Bobst, J.-C. Stehle, and D. Nardelli-Haefliger Intravaginal Immunization of Mice with Recombinant Salmonella enterica Serovar Typhimurium Expressing Human Papillomavirus Type 16 Antigens as a Potential Route of Vaccination against Cervical Cancer Infect. Immun., May 1, 2008; 76(5): 1940 - 1951. [Abstract] [Full Text] [PDF]

				G. G. Kenter, M. J.P. Welters, A.R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P.G. Vloon, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, et al. Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity Clin. Cancer Res., January 1, 2008; 14(1): 169 - 177. [Abstract] [Full Text] [PDF]

				M. J.P. Welters, G. G. Kenter, S. J. Piersma, A. P.G. Vloon, M. J.G. Lowik, D. M.A. Berends-van der Meer, J. W. Drijfhout, A. R. P.M. Valentijn, A. R. Wafelman, J. Oostendorp, et al. Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine Clin. Cancer Res., January 1, 2008; 14(1): 178 - 187. [Abstract] [Full Text] [PDF]

				S. Seresini, M. Origoni, F. Lillo, L. Caputo, A. M. Paganoni, S. Vantini, R. Longhi, G. Taccagni, A. Ferrari, C. Doglioni, et al. IFN-{gamma} Produced by Human Papilloma Virus-18 E6-Specific CD4+ T Cells Predicts the Clinical Outcome after Surgery in Patients with High-Grade Cervical Lesions J. Immunol., November 15, 2007; 179(10): 7176 - 7183. [Abstract] [Full Text] [PDF]

				S. H. van der Burg, S. J. Piersma, A. de Jong, J. M. van der Hulst, K. M. C. Kwappenberg, M. van den Hende, M. J. P. Welters, J. J. Van Rood, G. J. Fleuren, C. J. M. Melief, et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens PNAS, July 17, 2007; 104(29): 12087 - 12092. [Abstract] [Full Text] [PDF]

				K. M. E. Gallagher and S. Man Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women J. Gen. Virol., May 1, 2007; 88(5): 1470 - 1478. [Abstract] [Full Text] [PDF]

				S. Peng, C. Trimble, L. Wu, D. Pardoll, R. Roden, C.-F. Hung, and T.-C. Wu HLA-DQB1*02-Restricted HPV-16 E7 Peptide-Specific CD4+ T-Cell Immune Responses Correlate with Regression of HPV-16-Associated High-Grade Squamous Intraepithelial Lesions Clin. Cancer Res., April 15, 2007; 13(8): 2479 - 2487. [Abstract] [Full Text] [PDF]

				S. Dillon, T. Sasagawa, A. Crawford, J. Prestidge, M. K. Inder, J. Jerram, A. A. Mercer, and M. Hibma Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2 J. Gen. Virol., March 1, 2007; 88(3): 803 - 813. [Abstract] [Full Text] [PDF]

				S. J. Piersma, E. S. Jordanova, M. I.E. van Poelgeest, K. M.C. Kwappenberg, J. M. van der Hulst, J. W. Drijfhout, C. J.M. Melief, G. G. Kenter, G. J. Fleuren, R. Offringa, et al. High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer Cancer Res., January 1, 2007; 67(1): 354 - 361. [Abstract] [Full Text] [PDF]

				A. J. Garcia-Pineres, A. Hildesheim, R. Herrero, M. Trivett, M. Williams, I. Atmetlla, M. Ramirez, M. Villegas, M. Schiffman, A. C. Rodriguez, et al. Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. Cancer Res., November 15, 2006; 66(22): 11070 - 11076. [Abstract] [Full Text] [PDF]

				A. S. Gunnell, T. N. Tran, A. Torrang, P. W. Dickman, P. Sparen, J. Palmgren, and N. Ylitalo Synergy between Cigarette Smoking and Human Papillomavirus Type 16 in Cervical Cancer In situ Development Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2141 - 2147. [Abstract] [Full Text] [PDF]

				M. I.E. van Poelgeest, M. van Seters, M. van Beurden, K. M.C. Kwappenberg, C. Heijmans-Antonissen, J. W. Drijfhout, C. J.M. Melief, G. G. Kenter, T. J.M. Helmerhorst, R. Offringa, et al. Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment Clin. Cancer Res., July 15, 2005; 11(14): 5273 - 5280. [Abstract] [Full Text] [PDF]